THE ORPHAN RECEPTOR FAMILY RZR/ROR, MELATONIN AND 5-LIPOXYGENASE - AN UNEXPECTED RELATIONSHIP

被引:163
|
作者
CARLBERG, C [1 ]
WIESENBERG, I [1 ]
机构
[1] CIBA GEIGY AG, PHARMA FORSCH, CH-4002 BASEL, SWITZERLAND
关键词
NUCLEAR HORMONE RECEPTORS; LIGAND IDENTIFICATION; GENE REGULATION; NATURAL RESPONDING GENES; NUCLEAR SIGNALING OF MELATONIN;
D O I
10.1111/j.1600-079X.1995.tb00157.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The orphan receptors RZR alpha, RZR beta, ROR alpha 1, RZR alpha 2, ROR alpha 3, and ROR gamma form a subfamily within the superfamily of nuclear hormone receptors. Recently, experimental evidence that the pineal gland hormone melatonin is the natural ligand for these nuclear receptors has come to light. This discovery is rather surprising, given that most people in the field believed melatonin acts exclusively through membrane receptors. However, these new findings establish a nuclear signalling pathway for melatonin, i.e., direct ligand-induced control of target gene transcription, which most probably mediates part of the physiological functions of the hormone. Interestingly, the very recently identified first RZR/melatonin responding gene, 5-lipoxygenase, is not expressed in the brain and is not involved in circadian rhythmicity, but rather acts in the periphery, mainly in myeloid cells, as one of the key enzymes of allergic and inflammatory reactions. Thus, nuclear melatonin signalling opens up a new perspective in understanding the actions of the pineal gland hormone.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 50 条
  • [31] The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma
    Sorkness, CA
    PHARMACOTHERAPY, 1997, 17 (01): : S50 - S54
  • [32] The leukotriene receptor CYSLT1 and 5-lipoxygenase are upregulated in colon cancer
    Nielsen, CK
    Öhd, JF
    Wikström, K
    Massoumi, R
    Paruchuri, S
    Juhas, M
    Sjölander, A
    ADVANCES IN PROSTAGLANDIN, LEUKOTRIENE, AND OTHER BIOACTIVE LIPID RESEARCH: BASIC SCIENCE AND CLINICAL APPLICATIONS, 2003, 525 : 201 - 204
  • [33] Analysis of the 5-lipoxygenase promoter and characterization of a vitamin D receptor binding site
    Sorg, Bernd L.
    Klan, Niko
    Seuter, Sabine
    Dishart, David
    Radmark, Olof
    Habenicht, Andreas
    Carlberg, Carsten
    Werz, Oliver
    Steinhilber, Dieter
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2006, 1761 (07): : 686 - 697
  • [34] 5-lipoxygenase inhibitors with histamine H1 receptor antagonist activity
    Lewis, TA
    Bayless, L
    Eckman, JB
    Ellis, JL
    Grewal, G
    Libertine, L
    Nicolas, JM
    Scannell, RT
    Wels, BF
    Wenberg, K
    Wypij, DM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) : 2265 - 2268
  • [35] Involvement of nuclear receptor RZR/RORγ in melatonin-induced HIF-1α inactivation in SGC-7901 human gastric cancer cells
    Wang, Ri-Xiong
    Liu, Hui
    Xu, Li
    Zhang, Hui
    Zhou, Rui-Xiang
    ONCOLOGY REPORTS, 2015, 34 (05) : 2541 - 2546
  • [36] Dihydroxydocosahexaenoic acids of the neuroprotectin D family: synthesis, structure, and inhibition of human 5-lipoxygenase
    Butovich, Igor A.
    Lukyanova, Svetlana M.
    Bachmann, Carl
    JOURNAL OF LIPID RESEARCH, 2006, 47 (11) : 2462 - 2474
  • [37] Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis
    Saleh, Ramy R.
    Fuentes Antras, Jesus
    Peinado, Paloma
    Perez-Segura, Pedro
    Pandiella, Atanasio
    Amir, Eitan
    Ocana, Alberto
    CANCER TREATMENT REVIEWS, 2019, 77 : 11 - 19
  • [38] Structure–activity relationship in a series of natural and synthetic inhibitors of 5-lipoxygenase catalytic activity
    V. R. Khairullina
    I. A. Taipov
    A. Ya. Gerchikov
    F. S. Zarudii
    Pharmaceutical Chemistry Journal, 2012, 46 : 553 - 564
  • [39] 5-Lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci
    Tantisira, Kelan G.
    Lima, John
    Sylvia, Jody
    Klanderman, Barbara
    Weiss, Scott T.
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (03): : 244 - 247
  • [40] New frontiers in asthma therapy: Leukotriene receptor antagonists and 5-lipoxygenase inhibitors - Introduction
    Hendeles, L
    PHARMACOTHERAPY, 1997, 17 (01): : S1 - S2